Cannabinoids concentration variability in cannabis olive oil galenic preparations

Knowledge of the exact concentration of active compounds in galenic preparations is crucial to be able to ensure their quality and to properly administer the prescribed dose. Currently, the need for titration of extracts is still debated. Considering this, together with the absence of a standard preparation method, the aim of this study was to evaluate cannabinoids concentrations variability in galenic olive oil extracts, to evaluate the interlot and interlaboratory variability in the extraction yield and in the preparation composition.

[1]  R. Noyes,et al.  Analgesic Effect of Delta‐9‐Tetrahydrocannabinol , 1975, Journal of clinical pharmacology.

[2]  S. Bettiol,et al.  Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. , 2015, The Cochrane database of systematic reviews.

[3]  M. Maze,et al.  A Multicenter Dose-escalation Study of the Analgesic and Adverse Effects of an Oral Cannabis Extract (Cannador) for Postoperative Pain Management , 2006, Anesthesiology.

[4]  R. Pertwee,et al.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.

[5]  Arno Hazekamp,et al.  Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine , 2013 .

[6]  E. Perucca,et al.  Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy , 2019, Drugs.

[7]  E. Williamson,et al.  Cannabinoids in Clinical Practice , 2000, Drugs.

[8]  K. Müller-Vahl,et al.  Treatment of Tourette Syndrome with Cannabinoids , 2013, Behavioural neurology.

[9]  F. Vigevano,et al.  Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy , 2019, Pediatric Drugs.

[10]  D. BlindermanCraig,et al.  Cannabis for symptom control #279. , 2014 .

[11]  A. Jacklin,et al.  Pain relief with oral cannabinoids in familial Mediterranean fever , 1997, Anaesthesia.

[12]  B. Mccarberg.  Cannabinoids , 2007 .

[13]  M. Elsohly,et al.  Phytochemistry of Cannabis sativa L. , 2017, Progress in the chemistry of organic natural products.

[14]  Stephan Sanders,et al.  Pharmacopoeia , 2018, Oxford Handbook for the Foundation Programme.

[15]  M. Vadala',et al.  Spontaneous, anecdotal, retrospective, open‐label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan) , 2019, The International journal of pharmacy practice.

[16]  R. E. Hicks,et al.  The pharmacologic effects of daily marijuana smoking in humans , 1991, Pharmacology Biochemistry and Behavior.

[17]  P. Brusa,et al.  Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes , 2019, Front. Pharmacol..

[18]  M. Forni,et al.  Cellular Distribution of Canonical and Putative Cannabinoid Receptors in Canine Cervical Dorsal Root Ganglia , 2019, Front. Vet. Sci..

[19]  W. Powderly,et al.  Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. , 1997, Journal of pain and symptom management.

[20]  R. Jubb,et al.  PATIENTS AND METHODS , 1982 .

[21]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[22]  M. Huestis.  Human Cannabinoid Pharmacokinetics , 2007, Chemistry & biodiversity.

[23]  R. Pertwee,et al.  Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study , 2006, Journal of glaucoma.

[24]  C. Toth,et al.  An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy , 2011, Pain practice : the official journal of World Institute of Pain.

[25]  Giuseppe Cannazza,et al.  Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. , 2016, Journal of pharmaceutical and biomedical analysis.

[26]  K. Ethans,et al.  Nabilone for the treatment of pain in fibromyalgia. , 2008, The journal of pain : official journal of the American Pain Society.

[27]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[28]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.

[29]  V. Tawfik,et al.  Safety issues concerning the medical use of cannabis and cannabinoids. , 2005, Pain research & management.

[30]  Simona Pichini,et al.  Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry , 2017, Clinical chemistry and laboratory medicine.

[31]  M. Lynch,et al.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. , 2011, British journal of clinical pharmacology.

[32]  R. Pertwee.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.

[33]  M. Robbins,et al.  Cluster Attacks Responsive to Recreational Cannabis and Dronabinol , 2009, Headache.